• HOME
    • WHO WE ARE
    • VISION SCIENCE
  • ABOUT
    • WHAT WE BELIEVE
    • ORIENTATION
    • OUR BUSINESS
    • BRAND INDENTITY
  • TEAM
    • TEAM
    • ADVISORY BOD
  • PORTFOLIO
    • VENTURE CAPITAL
    • INDUSTRY INVESTMENT
    • INCUBATION
    • PORTFOLIO LITERATURE
  • RIMONCI INDEX
  • RESPECT
  • NEWS
    • INDUSTRY UPDATE
    • RIMONCI IN THE NEWS
  • CONTACT
  • LP Center
  • 中文
  • EN
  • Log in
  • Register
Log out
넳 넲

INDUSTRY UPDATE

  • 2021-03-25

    New Era Arrives in Glaucoma Medication, With Transformative Tech

    Market Scope estimates pharmaceutical companies 
    will earn $1.9 billion from glaucoma medications 
    in the US in 2021, after discounts and rebates, and $4.8 billion worldwide.

    more >

  • 2021-03-22

    Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion in 2026

    The retinal surgical device market is expected
     to total more than $1.14 billion in 2021, 
    with revenue rising to nearly $1.36 billion in 2026, according to a Market Scope report.

    more >

  • 2021-01-29

    COVID-19 and its impact on eye banking

    The COVID-19 pandemic has affected 
    all areas of medicine, including eye banking.

    more >

  • 2021-01-11

    BLOG: The top ophthalmology research articles from 2020

    Despite the COVID-19 pandemic, ophthalmology 
    research has continued at an exciting pace.

    more >

  • 2020-12-18

    Number of FDA new molecular entity approvals in 2020 similar to 2019

    Despite the COVID19 pandemic, the FDA 
    approved 47 new molecular entities in 2020
    including one for ophthalmology, compared with 48 in 2019, according to a speaker at the virtual Ophthalmology Innovation Summit Year in Review meeting.

    more >

  • 2020-12-07

    Cornea Products Market to Grow an Estimated 6.1 Percent Through 2025

    Market Scope’s “2020 Cornea Products Market 
    Report” was published in November

    more >

RIMONCI IN THE NEWS

  • NovaSight eyes FDA clearance with upcoming clinical trial

    The company’s digital therapy CureSight presents
     a new treatment method for amblyopia, also known
     as lazy eye, that doesn’t require patching.

    2021-03-16

  • EyeYon Medical Raises $25 million in Series C to Transform Corneal Care

    EyeYon Medical has developed the world's first synthetic 
    implant that enables doctors to treat chronic corneal edema 
    in a minimally invasive procedure without the use of human tissue or corneal donations.

    2021-03-15

  • 5 Top Pediatrics Startups Impacting the Healthcare Sector

    We analyzed 1.066 pediatrics startups. 
    InkSpace Imaging, Evoendo, NovaSight, 
    Fluid Pharma & HypnoVR develop 5 top solutions you should watch out for

    2021-03-10

  • A New Type of Corneal Availability

    Off-the-shelf, the artificial endothelial 
    implant EndoArt® aims to eliminate the need 
    for donor tissue in corneal edema treatment.

    2020-09-10

Address: Wework, 3F, Building 1, Zone A, Parkview Place, 2 East 4th Ring Rd, Chaoyang, Beijing 

© 2020 YUE ICP备19003617号

  • 끅
    • 客服电话

    • 88888888
  • 뀩
    • QQ客服
  • 뀥
    • 服务时间

    • 周一至周五 9:00-18:00
  • 낃
    • 微信二维码

  • 녕
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6
 本网站由阿里云提供云计算及安全服务
本网站支持 IPv6